TMED9: a potential therapeutic target and prognostic marker in glioma and its implications across pan-cancer contexts
BackgroundThe escalating global cancer burden, projected to reach 35 million new cases by 2050, underscores the urgent need for innovative cancer biomarkers to improve treatment efficacy and patient outcomes. The TMED family, particularly TMED9, has ga…